FDA has released the Guidance on Conduct of Clinical Trials of Medical Products during the COVID-19 pandemic

March 19, 2020

FDA has released the Guidance on Conduct of Clinical Trials of Medical Products during the COVID-19 pandemic

Yesterday morning FDA has released the Guidance on Conduct of Clinical Trials of Medical Products during the COVID-19 pandemic.

Here are the parts of Guideline recommendations that may be successfully followed with Flex Databases system:

Protocol deviations and IRBs/IEC submissions tracking

The Guideline states, that “FDA recognizes that protocol modifications may be required and that there may be unavoidable protocol deviations due to COVID-19 illness and/or COVID-19 control measures.”  In CRA Activity Management module, Flex Databases has inbuilt protocol deviations tracking – so a user can easily track all occurring deviation and make further reporting much more comfortable.

It also mentions that “Sponsors and clinical investigators are encouraged to engage with IRBs/IEC as early as possible when urgent or emergent changes to the protocol or informed consent are anticipated as a result of COVID-19.” Investigators & Sites Management module provides centralized ethic committees submissions and approval tracking to speed-up communications between both sides of the process.

Study data integrity

Several times FDA mentions the importance of trial integrity. The Guideline states, that “Efforts to minimize impacts on trial integrity, and to document the reasons for protocol deviations, will be important.” Flex Databases system is equipped with a full audit trail to ensure that no data is ever lost. Any activity inside of the system is reported precisely on Who does What, When, and Why.

Changes in policies and procedures

The Guideline says, that “Sponsors, clinical investigators, and IRBs should consider establishing and implementing policy and procedures, or revise existing policy and procedures, to describe approaches to be used to protect trial participants and manage study conduct during possible disruption of the study as a result of COVID-19 control measures at study sites.“

With Flex Databases system, our clients can optimize and automate the following:

  • study visits and procedures
  • study monitoring
  • adverse event reporting
  • changes in investigator(s), site staff, and/or monitor(s) secondary
  • and many more aspects of clinical trial management.

Flex Databases system ensures full business continuity, regulatory compliance, and data integrity, which importance is clearly stated in the Guideline. We are ready to provide any additional support and answer any questions to make a difficult period we are passing through to go as smoothly as it is ever possible. The level of service and system uptime will not be affected during the time of the crisis.

We carefully follow all changes in relevant regulations both on global and local levels and design system updates in compliance with the actual situation in the industry.

If you have any questions regarding Flex Databases compliance with the new FDA Guideline or any other needs, do not hesitate to contact us via contact@flexdatabases.com.

Stay at home,

Flex Databases

Blog

September 2, 2025
What CROs Should Look for in CTMS and eTMF During a Tender

When preparing a tender for a Clinical Trial Management System (CTMS) and an electronic Trial Master File (eTMF), CROs must choose solutions that meet sponsor expectations and improve operational efficiency while keeping studies inspection-ready. The right choice affects study delivery, compliance, and client satisfaction. Below are the key factors CROs should consider. Regulatory Compliance and […]

August 28, 2025
Integrations in Clinical Trials: An IT/ETL Perspective

How Flex Databases connects your study ecosystem – reliably, securely, and at scale.  Why integrations matter to sponsors and CROs  Integration means that data entered once in a system of record is propagated automatically wherever it is needed. For clinical operations teams this translates into:  Core integration patterns we see most often  1) EDC → […]

August 14, 2025
Key Changes to EU Pharmacovigilance Regulation: What You Need to Know

In July 2025, the European Commission adopted Commission Implementing Regulation (EU) 2025/1466, amending Regulation (EU) No 520/2012. The changes aim to strengthen pharmacovigilance, reduce unnecessary administrative burden, and align EU requirements with global best practices. Most provisions apply from 12 February 2026, with certain Eudravigilance updates taking effect in August 2025. Why the Changes Were […]

July 31, 2025
How Much ROI Can You Expect from eTMF and CTMS? 

A Comparative Look at Europe vs. US Markets  In clinical operations, time is money – but how much money can technology really save you? We analyzed the return on investment (ROI) for implementing electronic Trial Master File (eTMF) and Clinical Trial Management Systems (CTMS) based on real-world benchmarks. By modeling savings from reduced manual effort, […]

Contact us

Get in touch to discuss compliance, implementation, demos, pricing

We are here for all of your questions! Tell us more about yourself and we will organize a tailored live demo to show how you can power up your clinical trials processes with Flex Databases.